Seeking Alpha
 

Actavis plc. (ACT)

- NYSE
  • Apr. 10, 2012, 8:17 AM
    Watson Pharmaceuticals (WPI) receives FDA approval for a generic version of Vancocin and plans to begin shipping the products immediately.
    | Comment!
  • Mar. 21, 2012, 11:45 AM
    Watson Pharmaceuticals (WPI +0.8%) bounces around violently after word leaks that the company is close to signing off on a deal to buy Icelandic firm Actavis for €5B-€5.5B. Shares dropped sharply off the news, then reversed themselves in a slingshot move higher, and now stand +0.6%.
    | Comment!
  • Mar. 15, 2012, 2:58 PM
    Mylan (MYL +1.4%) has pulled out of discussions to buy a stake in Italian pharmaceutical firm Rottapharm after the selling family wouldn't agree to give up control, nor compromise enough on price. Rottapharm has also held talks with Watson Pharmaceuticals (WPI -0.2%) and Forest Labs (FRX +0.1%), however Watson doesn't appear likely to be a buyer.
    | Comment!
  • Mar. 2, 2012, 10:36 AM
    Watson Pharmaceuticals (WPI -0.3%) confirms that it launched a generic version of Prometrium as part of an agreement with Abbott Laboratories (ABT +0.1%). Over the last 12-month reporting period, Prometrium had sales of close to $198M.
    | Comment!
  • Feb. 27, 2012, 7:21 AM
    Watson Pharmaceutical (WPI) confirms that it received a complete response letter from the FDA spelling out concerns over its progesterone vaginal gel designed to reduce the risk of preterm births. The letter states that the treatment doesn't meet the level of statistical significance expected to support the approval of a product from a single trial.
    | Comment!
  • Feb. 14, 2012, 9:02 AM
    More on Watson (WPI +2.2%) Q4: Net income more than quintuples to $94.8M, with earnings boosted by generic versions of Pfizer's Lipitor cholesterol treatment and J&J's Concerta ADHD drug. Watson ups its 2012 EPS guidance to $5.50-$5.80 from $5.25-$5.55 and vs. $5.60 consensus. Also ups rev forecast by $100M to $5.4B.
    | Comment!
  • Feb. 14, 2012, 7:19 AM
    Watson Pharmaceuticals (WPI): Q4 EPS of $1.77 beats by $0.02. Revenue of $1.55B (+81.5% Y/Y) in-line. (PR)
    | Comment!
  • Feb. 14, 2012, 12:05 AM
    Notable earnings before Tuesday's open: AVP, BWA, FOSL, GT, HCP, HSP, HST, KORS, MMC, OMC, TRP, UTHR, VAL, WPI
    | Comment!
  • Feb. 13, 2012, 5:30 PM
    Notable earnings before Tuesday's open: AVP, BWA, FOSL, GT, HCP, HSP, HST, KORS, MMC, OMC, TRP, UTHR, VAL, WPI
    | Comment!
  • Feb. 13, 2012, 7:01 AM
    Watson Pharmaceuticals (WPI) seeks FDA approval to market generic Beyaz after facing a lawsuit from Bayer (BAYRY.PK) challenging a patent on the drug. The firm says it believes that it may be a "first applicant" to file an ANDA for the generic version of Beyaz and should be entitled to 180 days of generic market exclusivity.
    | Comment!
  • Feb. 10, 2012, 2:58 PM
    Watson Pharmaceuticals (WPI -0.2%) faces a lawsuit from Bayer (BAYRY.PK) over accusations that it violated the drug maker's birth control patents, according to Bloomberg.
    | Comment!
  • Feb. 3, 2012, 9:52 AM
    Watson Pharmaceuticals (WPI -0.6%) responds to increasing investment chatter over a Lipoderm patent challenge with a rather tepid statement that says the drug is still on track. The firm reiterates its view that it will land tentative FDA approval before July 15.
    | Comment!
  • Jan. 26, 2012, 10:17 AM
    Momenta Pharmaceuticals (MNTA -21.3%) plummets on heavy volume, reacting to reports that Watson Pharmaceuticals (WPI +1.6%) partner Amphastar won an appeals court stay involving its generic Lovenox blood thinner treatment. A preliminary injunction preventing the launch of a generic version of Lovenox had been granted in October.
    | Comment!
  • Jan. 25, 2012, 1:46 PM
    Watson Pharmaceuticals (WPI +2.8%) gets a lift from a Morgan Stanley upgrade to Overweight, noting that potential earnings upside and a higher valuation could drive the shares up 16% or more.
    | Comment!
  • Jan. 24, 2012, 11:24 AM
    Canaccord Genuity weighs in on Columbia Laboratories (CBRX +2.2%) after the firm was rocked by a FDA rejection of its preterm birth prevention gel. Though analyst Randall Stanicky acknowledges the "disappointment," he still sees potential for CBRX and rival Watson Pharmaceuticals (WPI -3.4%) on possible M&A activity and the under-leveraged balance sheets the firms carry.
    | Comment!
  • Jan. 24, 2012, 6:48 AM
    Watson Pharmaceuticals (WPI) announces prelim FY11 EPS of $4.75-4.77 vs. $4.61 consensus, and FY11 revenue of $4.57B vs. $4.53B consensus. For FY12, the company sees EPS of $5.25-5.55 and revenue of $5.3B. (PR) (earlier)
    | Comment!
Visit Seeking Alpha's
ACT vs. ETF Alternatives
Company Description
Actavis PLC specialty pharmaceutical company engaged in developing, manufacturing and distributing generic, brand and biosimilar products.
Sector: Healthcare
Industry: Drugs - Generic
Country: United States